May 25, 2022CorporateTerumo Blood and Cell Technologies Inaugurates Second Manufacturing Facility in Colorado
May 17, 2022CorporateTerumo Pharmaceutical Solutions Offers Pre-Fillable Syringe Solutions for Demanding Low Dose Applications Such as Ophthalmic
May 16, 2022CorporateTerumo Announces Change in Indication for Dexcom G6 CGM System in Japan Adjunctive use of Blood Glucose Meter Principally Not Required
Investors Japanese Financial Results for the Fiscal Year Ended 3/2022 May 12, 2022 IR Library Audio Webcast Stock Quote Prime Market of TSE: Last Trade JPY Change JPY (%) Volume View Chart Top Management Message Shinjiro Sato, President and CEO 5-Year Growth Strategy 2022 - 2026 Terumo Report Sustainability What's New May 16, 2022 Q&A regarding Financial Results for the FYE 3/2022 May 13, 2022 Audio webcast regarding Financial Results for FYE 3/2022 May 12, 2022 Presentation regarding Financial Results for FYE 3/2022 February 14, 2022 Q&A regarding Financial Results for the Third Quarter of FYE 3/2022 February 10, 2022 Audio webcast regarding Financial Results for the Third Quarter of FYE 3/2022 View all Business Overview Introduction to the businesses operated by the Terumo Group /business Technology Introduction to Terumo's research and development activities and production system /technology